Use of daclizumab in the immunosuppression of high-risk kidney and kidney/pancreas recipients: Warsaw transplantation center experience

Saved in:

Bibliographic Details
Published in:	Transplantation proceedings Vol. 34; no. 2; pp. 551 - 552
Main Authors:	Bączkowska, T, Kukula, K, Nowacka-Cieciura, E, Cieciura, T, Lewandowska, D, Ciecierski, R, Grochowiecki, T, Rowinski, W, Szmidt, J, Durlik, M, Lao, M
Format:	Journal Article Conference Proceeding
Language:	English
Published:	New York, NY Elsevier Inc 01-03-2002 Elsevier Science
Subjects:	Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Combined surgery. Multiple transplantations Daclizumab Female Graft Rejection - drug therapy Graft Rejection - epidemiology Humans Immunoglobulin G - therapeutic use Immunomodulators Immunosuppressive Agents - therapeutic use Incidence Kidney Transplantation - immunology Male Medical sciences Middle Aged Pancreas Transplantation - immunology Pharmacology. Drug treatments Poland Renal Dialysis - statistics & numerical data Retrospective Studies Risk Factors Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Poland Europe Human High risk Concurrent Transplantation Monoclonal antibody Homotransplantation Kidney Daclizumab Immunosuppression Treatment Urinary system Combined surgery Surgery Graft Clinical trial Immunosuppressive agent Pancreas
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!